Figure 6. SMC and immune checkpoint inhibitor treatment in mouse models of glioblastoma leads to changes in immune effector cell infiltration.

(a) Mice bearing intracranial CT-2A tumours were treated at the indicated times with vehicle or 75 mg kg⁻¹ LCL161 orally (SMC) and 250 μg IgG or anti-PD-1 i.p. Mice were euthanized on day 27 post implantation. (b–e) Viable T-cells isolated from tumours were processed for flow cytometry using the following antibodies: CD45 (PE-Cy5), CD3 (APC), CD4 (PE-Cy7), CD8 (BV786), CD25 (BV605) and PD-1 (BV421). (f,g) Viable cells from the experiment in (a) were processed for flow cytometry using the following antibodies: CD45 (BV605), CD11b (APC-Cy7), Gr1 (BV786), F4/80 (PE) and CD3 (APC). All panels: Crosses depict mean, solid horizontal lines depict median, boxes depict 25th to 75th percentile, and whiskers depict min–max range of the values. Significance was compared with vehicle and IgG-treated mice as assessed by ANOVA with Dunnett’s multiple comparison test. *P<0.05; **P<0.01. n=6 for each treatment group.